Ultragenyx Pharmaceutical (RARE) Competitors

Genmab A/S (NASDAQ:GMAB) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Is GMAB or RARE more profitable?

Genmab A/S has a net margin of 36.30% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Genmab A/S's return on equity of 16.78% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
Ultragenyx Pharmaceutical	-101.60%	-185.70%	-38.25%

Which has higher valuation and earnings, GMAB or RARE?

Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.73	$1.14B	$1.74	12.84
Ultragenyx Pharmaceutical	$560.23M	7.02	-$569.18M	-$6.34	-6.72

Which has more risk & volatility, GMAB or RARE?

Genmab A/S has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Do analysts prefer GMAB or RARE?

Genmab A/S currently has a consensus price target of $42.17, suggesting a potential upside of 88.75%. Ultragenyx Pharmaceutical has a consensus price target of $93.50, suggesting a potential upside of 119.54%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Do institutionals and insiders hold more shares of GMAB or RARE?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media refer more to GMAB or RARE?

In the previous week, Genmab A/S had 4 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 18 mentions for Genmab A/S and 14 mentions for Ultragenyx Pharmaceutical. Genmab A/S's average media sentiment score of 1.00 beat Ultragenyx Pharmaceutical's score of 0.29 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer GMAB or RARE?

Ultragenyx Pharmaceutical received 671 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.46% of users gave Ultragenyx Pharmaceutical an outperform vote while only 62.84% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 164 62.84%	Underperform Votes 97 37.16%
Ultragenyx Pharmaceutical	Outperform Votes 835 77.46%	Underperform Votes 243 22.54%

Summary

Genmab A/S beats Ultragenyx Pharmaceutical on 11 of the 19 factors compared between the two stocks.